Global Glycosylated Hemoglobin And C Peptide Market 2022 – 2028: Increasing Prevalence of Diabetes Across the Globe and Growing Geriatric Population Drives Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Glycosylated Hemoglobin And C Peptide Market 2022-2028” report has been added to ResearchAndMarkets.com’s offering.

The global glycosylated hemoglobin and c peptide market is anticipated to grow at a considerable CAGR during the forecast period.

The market is expected to grow with some emerging trends which includes increasing prevalence of diabetes across the globe and growing geriatric population, growing advancements in pharmaceutical and biopharmaceutical sectors and on-going research on C-peptide and glycosylated hemoglobin.

However, these tests are sometimes less accurate if the patient is dealing with other diseases this may affect the outcome of the product, hence can be a restrain for the market growth.

The global glycosylated hemoglobin and c peptide market is segmented based on product and application. Based on product, the market is segmented into a tablet, capsules, injectable, and others. Based on application the market is sub-segmented into oncology, blood disorder, diabetes, and others.

Among these, the blood disorder segment is anticipated to grow at a widespread rate during the forecast period . Blood disorders are increasing in many parts of the world. According to WHO, in the world, around 42% of children whose age is less than 5 years and around 40 % of pregnant women in the world are suffering from anemia.

For instance, in Oct 2021, a Nutritionist at the International crop research institute for the semi-arid tropics have suggested that the use of millets can improve hemoglobin and serum levels can reduce anemia.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia-Pacific is going to be a good market for glycosylated hemoglobin and c peptide during the forecasted period. As per the international agency on cancer research, there are around 241,270 patients of non-Hodgkin lymphoma in Asia in the year 2020. For instance, in June 2021, Genentech has announced new data insights on Policy which will be used in Non-Hodgkin lymphoma.

The major companies serving the global glycosylated hemoglobin and c peptide market include Pfizer Inc., Medtronic, F.Hoffmann-La Roche Ltd., Sandoz International GmBh, Biocon Ltd., and others. The market players are adopting different market strategies such as mergers and acquisitions, new product launches, business expansion, partnership collaboration, and others.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

3. Competitive Landscape

3.1. Pfizer Inc.

3.1.1. Overview

3.1.2. Financial Analysis

3.1.3. SWOT Analysis

3.1.4. Recent Developments

3.2. Medtronic Plc

3.2.1. Overview

3.2.2. Financial Analysis

3.2.3. SWOT Analysis

3.2.4. Recent Developments

3.3. F. Hoffmann-La Roche Ltd

3.3.1. Overview

3.3.2. Financial Analysis

3.3.3. SWOT Analysis

3.3.4. Recent Developments

3.4. Sandoz International GmbH

3.4.1. Overview

3.4.2. Financial Analysis

3.4.3. SWOT Analysis

3.4.4. Recent Developments

3.5. Biocon Ltd.

3.5.1. Overview

3.5.2. Financial Analysis

3.5.3. SWOT Analysis

3.5.4. Recent Developments

3.6. Key Strategy Analysis

3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

4.1. Global Glycosylated hemoglobin and c peptides Market by Product

4.1.1. Tablet

4.1.2. Capsules

4.1.3. Injectable

4.1.4. Others

4.2. Global Glycosylated hemoglobin and c peptides Market by Application

4.2.1. Oncology

4.2.2. Blood disorder

4.2.3. Diabetes

4.2.4. Other

5. Regional Analysis

5.1. North America

5.1.1. United States

5.1.2. Canada

5.2. Europe

5.2.1. UK

5.2.2. Germany

5.2.3. Italy

5.2.4. Spain

5.2.5. France

5.2.6. Rest of Europe

5.3. Asia-Pacific

5.3.1. China

5.3.2. India

5.3.3. Japan

5.3.4. South Korea

5.3.5. Rest of Asia-Pacific

5.4. Rest of the World

6. Company Profiles

6.1. Novartis AG

6.2. Sanofi SA

6.3. Dr Reddy’s Laboratories Ltd.

6.4. Celltrion Healthcare Co. Ltd.

6.5. Medtronic PLC

6.6. Lee BioSolution

6.7. Portea Medical

For more information about this report visit https://www.researchandmarkets.com/r/hr706p

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900